Clinical trials: Ophthalmic Solutions
Presbyopia
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia.
- Trial name
- OPSIS (NCT05665387)
- Testing
- 0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution
- Where
- 12 sites in United States
- Volunteers
- 79 people
- Sponsor
- Santen Inc.
Anesthesia, Local
A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US.
- Trial name
- NCT04513652
- Testing
- AG-920
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Dry Eye Disease
A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease
This study will evaluate the safety and efficacy of a carboxymethylcellulose based eye drop formulation compared with carboxymethylcellulose based preservative-free lubricant eye drops (OPTIVE™) in subjects with dry eye disease.
- Trial name
- NCT01664949
- Testing
- Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
- Where
- 12 sites in Australia, Belgium and 6 more
- Volunteers
- 460 people
- Sponsor
- Allergan
Allergic Conjunctivitis
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic…
- Trial name
- NCT03660878
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
The objective of the study was to evaluate whether timolol hemihydrate is more comfortable upon instillation than timolol maleate in sorbate. This was an observational study.
- Trial name
- NCT00823043
- Testing
- timolol hemihydrate, timolol maleate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Vistakon Pharmaceuticals
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Allergic Conjunctivitis
A Six-Week Safety Study of an Investigational Ophthalmic Solution
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
- Trial name
- NCT01698814
- Testing
- AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye Disease
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Primary Objectives: To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
- Trial name
- PROTEGO-2 (NCT05136170)
- Testing
- Cenegermin, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 85 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Syndromes
Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
This study will evaluate the safety, efficacy, and acceptability of an eye drop formulation in subjects with dry eye disease.
- Trial name
- NCT01459588
- Testing
- Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Eye Drop Formulation B, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Dry Eye
Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery
This study is designed to assess the tolerability and comfort of peri-operative 0.3% hypromellose eye drops in LASIK surgery patients and to assess whether pre-operative 0.3% hypromellose eye drops add to post-operative comfort…
- Trial name
- NCT00909324
- Testing
- Pre-LASIK 0.3% hypromellose, Post-LASIK 0.3% hypromellose
- Where
- India
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Safety, Tolerability
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Clinical phase I, controlled, non comparative, open, single center study evaluating the safety and tolerability of ophthalmic solution PRO-172 when applied on the ocular surface of healthy volunteers.
- Conditions
- Safety, Tolerability, Ocular Surface, Ocular Comfort
- Trial name
- PRO-172 (NCT04693429)
- Testing
- Bepotastine Besilate
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01743027
- Testing
- AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1%
- Volunteers
- 902 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry…
- Trial name
- NCT03404115
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Cataract
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
- Trial name
- NCT00870103
- Testing
- Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Dry Eye
A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
The primary objectives of this investigation are to show that the performance of CBL-101 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days…
- Trial name
- NCT02975102
- Testing
- CBL-101 Eye Drops, Vismed® Multi Eye Drops
- Where
- 2 sites in Belgium, France
- Volunteers
- 87 people
- Sponsor
- Laboratoire Chauvin
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC